PF icon
Feature Partner

Psilotec Health Solutions

Quick Overview of Psilotec Health Solutions

Company Status
Parent Company
CSE Ticker
OTC Ticker

Company Summary


PsiloTec is developing a unique range of psilocybin therapy mushrooms with multiple layers of intellectual property (IP) protection, produced to the highest standards required when using Good Manufacturing Process (GMP) for organic products.

Their team has comprehensive experience in clinical research with more than 300 clinical studies in the mental health space.

Psilotec is pursuing development of unique products, product combinations, and formulations to increase revenue from multiple sources.

Psilocybin Cultivation

Psilotec is in the process of securing a 23,000 sq. ft. growing facility exclusively designed for PsiloTec’s needs. All production will be carried out under the highest GMP quality standards.

They will use mycology experts and xclusively licensed IP to enhance yields and speed of harvest with intention to develop unique strains of mushrooms secured along with ongoing research and development of new IP protected strains.

Anticipated production of psilocybin for clinical trials beginning Q2, 2021, at partnered sites with production commencing in Alberta in Q4, 2021.


​Using a wide range of state-of-the-art technology, including multiple in-house innovations, Psilotec intends to use virtual therapy sessions so that individuals can be treated locally while remaining connected to central experienced staff.

Individuals will be treated with standardized IP-protected equipment. By offering central monitoring in real time, highly experienced therapists can also offer appropriate psychological support as needed throughout every session. Live and continuous biofeedback offers more layers of support and re-assurance, and can help ensure that every patient gains the most out of their therapeutic experience.

They aim to have over 1,000 fully-trained therapists available before the end of 2022.


Dr. Peter Silverstone, Chief Executive Officer & Director
Dr. Silverstone has a 35 year background in brain and pharmaceutical research. He has been involved in the successful development of multiple health related start ups. He has highly relevant expertise in international drug and IP development and regulatory issues.  Dr. Silverstone is a Professor in the Department of Psychiatry at the University of Alberta.
Louise Duchesne, CPA, CA, Chief Financial Officer
Ms. Duchesne brings over 30 years of financial accounting, tax, regulatory compliance, capital markets, and investment industry experience. Ms. Duchesne is a co-founder and managing director of Lightyear Capital Inc., a Calgary-based investment dealer and is responsible for the oversight of the firm.She holds a Bachelor of Commerce degree from McGill University, a CPA, CA designation and is a member of the Chartered Professional Accountants of Alberta.
Scott Phillips, MBA, CPA, CA, Chief Operating Officer
Mr. Phillips has over 20 years experience in operations and led the logistics network for the nation's 3rd largest private lab, with a team of over 65 employees and contracts covering Western Canada. In 2019, Mr. Phillips was named one of the Top 40 under 40 in Edmonton. He is currently the Chair for the CASA Foundation and Director at Our House, a male addiction recovery centre.